Navigation Links
Researchers narrow the search for biomarkers of drug resistance in head and neck cancer patients
Date:5/31/2013

CHICAGO, IL (May 29, 2013)Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximaba type of monoclonal antibody. The FDA approved the drug, in combination with radiation or as a second-line drug after chemotherapy had failed, in 2006. In 2011, the drug was approved as a first-line treatment for metastatic disease, in combination with chemotherapy.

"Targeted therapies should optimally be used in patients who are selected for sensitivity or the absence of sensitivity, and we've been handicapped by not knowing the resistance in head and neck cancers," says Barbara Burtness, MD, chief of head and neck medical oncology at Fox Chase and chair of the Eastern Cooperative Oncology Group (ECOG), a National Cancer Institute-funded team of researchers who organize and carry out clinical trials.

Before cetuximab, head and neck cancer patients' only options were conventional platinum-based chemotherapy and radiation, says Burtness. But since tumors in different people may have different biologies, not all patients respond to same treatment in the same ways. Those whose tumors do not respond to cetuximab suffer the drug's side effects without gaining benefits. Biomarkers can help providers match appropriate treatments to disease. They may also provide inroads toward re-sensitizing tumors to treatment by cetuximab.

She and researchers from the ECOG head and neck committee have been studying the biology of cetuximab-resistant and non-resistant tumors in search of telltale molecular signatures, or biomarkers, that might indicate if a disease will respond to the drug. The researchers have zeroed in on two potential biomarkers.

Cetuximab targets the epidermal growth factor receptor (EGFR) in a cancerous cell. When EGFR is activated, it sends signals through the cell using several pathways. Burtness and her team suspected that abnormalities in one of those pathways may be connected to cetuximab resistance. Their search for related molecules led them to a protein called PTEN and a gene called PIK3CA. They hypothesized that cells which either don't express PTEN or have a mutation in the PIK3CA gene are more likely to be unresponsive to cetuximab.

To test the biomarkers, they used tumor samples from a small phase III randomized trial that compared chemotherapy with cetuximab to chemotherapy alone for patients with head and neck cancer. That study showed that cetuximab improved responses in patients with metastatic/recurrent head and neck cancer who were receiving chemotherapy. A subsequent larger European study called EXTREME, showed that cetuximab conferred a significant survival benefit to these patients. Those studies did not identify which patients were most likely to respond to the drug.

Burtness first used tumor samples from Fox Chase Cancer Center to develop tools designed to show if a test sample had the mutation or lacked PTEN. Then, she and her collaborators analyzed 67 samples for PTEN and found 23 (34 percent) did not express the protein. The researchers studied the PIK3CA gene in 52 separate samples and found mutations in two samples (four percent). When the researchers grouped together samples that either did not express PTEN or had the PIK3CA mutation, they did not identify a significant difference in overall survival or progression-free survival, compared to the rest of the sample population.

However, the analyses suggest that for patients who expressed PTEN and lacked the PIK3CA mutation, cetuximab increased progression-free survival and overall survival each by more than a month, compared to patients lacking PTEN or with the mutation.

Burtness says these results are promising, but they're still early. "It's a small sample, and clearly more work needs to be done on larger sample sets," she says. "But we do think that this combination biomarkerthe signature of PTEN loss and/or PIK3CA mutationmight point the way to those patients who are resistant to cetuximab."

A critical biomarker may also help researchers better understand the biology of tumors that don't respond to treatment with the drug. That knowledge could point to the use of other treatments, either new or existing, to re-sensitize a tumor to cetuximab.

"If you find a molecule that can be targeted that seems to produce resistance, it would make sense to look at cetuximab in combination with something that turns off the abnormality in the chemical pathway," says Burtness.


'/>"/>

Contact: Diana Quattrone
diana.quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Researchers investigate a less toxic radiation treatment for HPV-Positive oropharynx cancer
2. Researchers discover new weapon in fight against cervical cancer
3. Researchers gain insight into key protein linked to cancers, neurodegenerative disorders
4. Researchers identify novel approach to create red blood cells, platelets in vitro
5. Researchers shed new light on egg freezing success rates
6. Junk DNA plays active role in cancer progression, researchers find
7. Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas
8. Stanford researchers identify genetic suspects in sporadic Lou Gehrigs disease
9. Researchers identify first drug targets in childhood genetic tumor disorder
10. Researchers find common childhood asthma unconnected to allergens or inflammation
11. Researchers identify networks of neurons in the brain that are disrupted in psychiatric disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is ... powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been ... pleased to be the first in Arkansas to introduce the most powerful SCS system ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of ... With the average cost of healthcare rising and the U.S. senior population expected to ... affordability of where they live. An annual 2017 report looked at a variety of ...
(Date:5/26/2017)... ... 2017 , ... via seating is proud to partner with ... specifically designed for clinical areas. Genie Copper Mesh is a crossover chair for ... provide customers with a game changing chair that is affordably priced,” Chas Hepler ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on ... will continue to be available at a discounted crowdfunding price on Indiegogo . ... they are, I also wanted to bring a fidget toy to the market that ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Inc. (Nasdaq: HOLX ) announced today the ... April 1, 2017 .   GAAP diluted earnings per ... prior year period as the sale of the blood ... diluted EPS of $0.50 increased 6.4%.  Revenue of $715.4 ... Excluding the effects of blood screening and the acquired ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: ... Inc. ("WRB"), a health care service center company ... WRB specializes in relationship management programs for leading ... WRB will join Envoy ... support services for manufacturers, biotech firms, and other service ...
Breaking Medicine Technology: